Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy

Autor:	Labrador, Jorge, Luno, Elisa, Vellenga, Edo, Brunet, Salut, Gonzalez-Campose, Jose, Chillon, Maria C., Holowiecka, Aleksandra, Esteve, Jordi, Bergua, Juan, Gonzalez-Sanmiguel, Jose D., Gil, Cristina, Tormo, M., Salamero, Olga, Manso, Felix, Fernandez, Isolda, de laSerna, Javier, Moreno, Maria-Jose, Perez-Encinas, M., Krsnik, Isabel, Ribera, Josep-Maria, Cervera, Jose, Calasanz, Maria J., Boluda, Blanca, Sobas, Marta, Lowenberg, Bob, Sanz, Miguel A., Montesinos, Pau, Palmer, L., Fernandez, Ciarlo, S., Bezares, F., Rojas, F., Longoni, H., Gelemur, M., Fazio, P., Canepa, C., Saba, S., Balladares, G., Negri, P., Giunta, M., Milone, J., Prates, M., Lafalse, D., Sossa, C., Jaramillo, F., Mayer, J., Ramos, F., Martinez, J., de Groot, M. R., Schouten, H. C.
Přispěvatelé:	Hematology, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Stem Cell Aging Leukemia and Lymphoma (SALL), Interne Geneeskunde, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, MUMC+: MA Hematologie (9)
Jazyk:	angličtina
Rok vydání:	2019
Předmět:	Male Cancer Research complex karyotype ANTHRACYCLINE MONOCHEMOTHERAPY medicine.medical_treatment Abnormal Karyotype chemotherapy Gastroenterology Leukocyte Count 0302 clinical medicine Leukemia Promyelocytic Acute Recurrence Acute promyelocytic leukemia Antineoplastic Combined Chemotherapy Protocols PROGNOSTIC-SIGNIFICANCE Cumulative incidence ATRA Child In Situ Hybridization Fluorescence Aged 80 and over relapse PETHEMA Incidence (epidemiology) ADDITIONAL CHROMOSOME-ABNORMALITIES Age Factors Hematology Middle Aged Prognosis ARSENIC TRIOXIDE FLT3 MUTATIONS Leukemia Treatment Outcome Oncology Child Preschool 030220 oncology & carcinogenesis Cytogenetic Analysis Female Adult medicine.medical_specialty CYTOGENETIC CHANGES Adolescent Young Adult 03 medical and health sciences Internal medicine Statistical significance Complex Karyotype medicine Humans Clinical significance Aged CONSOLIDATION THERAPY Chromosome Aberrations Chemotherapy business.industry medicine.disease RISK-ADAPTED TREATMENT TRANS-RETINOIC ACID ATRA Acute promyelocytic leukemia chemotherapy complex karyotype prognostic relapse business prognostic 030215 immunology
Zdroj:	LEUKEMIA & LYMPHOMA r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA instname Leukemia & Lymphoma, 60(5), 1146-1155. Informa Healthcare r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante Leukemia & Lymphoma, 60(5), 1146-1155. TAYLOR & FRANCIS LTD Leukemia & Lymphoma, 60(5), 1146-1155. Routledge/Taylor & Francis Group
ISSN:	1042-8194
Popis:	Although additional cytogenetic abnormalities (ACA) do not affect the prognosis of patients with t(15;17) acute promyelocytic leukemia (APL), the role of a complex karyotype (CK) is yet to be clarified. We aimed to investigate the relationship of CK with relapse incidence in 1559 consecutive APL patients enrolled in three consecutive trials. Treatment consisted of AIDA induction followed by risk-adapted consolidation. A CK (CK) was defined as the presence of ≥2 ACA, and a very CK (CK+) as ≥3 ACA. Eighty-nine patients (8%) had a CK, of whom 41 (4%) had CK+. The 5-year cumulative incidence of relapse (CIR) in patients with CK was 18%, and 12% in those with
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25ce879dfb378953de6edc47e3b66161 https://hdl.handle.net/11370/4bfa151c-1536-422c-89b3-603a8cf36dbf Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.